Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Sweet K, Bhatnagar B, Döhner H, Donnellan W, Frankfurt O, Heuser M, Kota V, Liu H, Raffoux E, Roboz GJ, Röllig C, Showel MM, Strickland SA Jr, Vives S, Tang S, Unger TJ, Joshi A, Shen Y, Alvarez MJ, Califano A, Crochiere M, Landesman Y, Kauffman M, Shah J, Shacham S, Savona MR, Montesinos P. Sweet K, et al. Among authors: showel mm. Leuk Lymphoma. 2021 Dec;62(13):3192-3203. doi: 10.1080/10428194.2021.1950706. Epub 2021 Jul 29. Leuk Lymphoma. 2021. PMID: 34323164 Clinical Trial.
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE. Zeidan AM, et al. Among authors: showel mm. Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18. Br J Haematol. 2012. PMID: 22594769 Free PMC article. Clinical Trial.
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.
Norsworthy KJ, Cho E, Arora J, Kowalski J, Tsai HL, Warlick E, Showel M, Pratz KW, Sutherland LA, Gore SD, Ferguson A, Sakoian S, Greer J, Espinoza-Delgado I, Jones RJ, Matsui WH, Smith BD. Norsworthy KJ, et al. Leuk Res. 2016 Oct;49:90-7. doi: 10.1016/j.leukres.2016.09.003. Epub 2016 Sep 3. Leuk Res. 2016. PMID: 27619199 Free PMC article. Clinical Trial.
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD. Norsworthy KJ, et al. Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Leuk Res. 2017. PMID: 28869816 Free PMC article. Review.
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. Zeidner JF, et al. Among authors: showel mm. Leukemia. 2020 Jun;34(6):1563-1576. doi: 10.1038/s41375-019-0693-4. Epub 2020 Jan 3. Leukemia. 2020. PMID: 31900407 Free PMC article. Clinical Trial.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. Borthakur G, et al. Among authors: showel mm. Cancer. 2021 Apr 15;127(8):1246-1259. doi: 10.1002/cncr.33338. Epub 2020 Dec 3. Cancer. 2021. PMID: 33270904 Free article. Clinical Trial.
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Webster JA, Yogarajah M, Zahurak M, Symons H, Dezern AE, Gojo I, Prince GT, Morrow J, Jones RJ, Smith BD, Showel M. Webster JA, et al. Leuk Lymphoma. 2021 Dec;62(13):3181-3191. doi: 10.1080/10428194.2021.1948029. Epub 2021 Jul 21. Leuk Lymphoma. 2021. PMID: 34284701 Free PMC article. Clinical Trial.
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Ambinder A, Smith M, Tsai HL, Varadhan R, DeZern A, Dalton W, Gocke C, Webster J, Gondek L, Gojo I, Ali SA, Huff CA, Swinnen L, Wagner-Johnston N, Showel M, Prince G, Borrello I, Bolaños-Meade J, Luznik L, Jain T, Imus P, Fuchs E, Ambinder R, Gladstone DE, Levis M, Jones R, Ghiaur G, Smith BD. Ambinder A, et al. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):260-269. doi: 10.1016/j.clml.2021.09.022. Epub 2021 Oct 9. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34750086 Free PMC article.
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Karp JE, et al. Among authors: showel mm. Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24. Haematologica. 2012. PMID: 22733022 Free PMC article. Clinical Trial.
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Karp JE, et al. Among authors: showel mm. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23. Clin Cancer Res. 2012. PMID: 23092873 Free PMC article. Clinical Trial.
32 results